Perceptions on the feasibility of decentralizing phlebotomy services in community anti-retroviral therapy group model in Lusaka, Zambia.
ART
CAG
Decentralization
HIV/AIDS
Phlebotomy
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
14 Aug 2019
14 Aug 2019
Historique:
received:
13
05
2019
accepted:
31
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
20
12
2019
Statut:
epublish
Résumé
The focus of the community anti-retroviral therapy Group model is on drug refill, adherence and support groups. However, laboratory services are completely neglected in this model, and stable patient still have to go to the clinic for blood draws after drugs refills from the community. Due to the introduction of new ART drugs, the guidelines now recommend the use of viral loads to guide decision in switching all patients from NNRTI to dolutegravir based first line ART regimens. But the national viral load testing coverage stands at 37% and and falls short of meeting the global UNAIDS and phlebotomy delivery system is congested. The purpose of this study was to identify the perceptions in decentralizing phlebotomy services into the community anti-retroviral therapy Group model. A qualitative case study design was used. Data were collected through ten Focused group discussions among community anti-retroviral therapy Group members, community and health care workers at anti-retroviral therapy clinics and in-depth interviews with five key informants. Data were managed with the help of Nvivo version 10 and analyzed using thematic method. Positive perceptions were identified as those which contributed to decongesting phlebotomy rooms, reduced missing phlebotomy appointments, work Load, and lost results. Improved quality of phlebotomy service delivery and testing coverage, innovative access to laboratory services and encouraged patient's accountability. The negative perceptions were compromised sample integrity, inability to perform prevention control and patients less contact with clinicians. The study has demonstrated that decentralizing phlebotomy services within the CAG model has greater potential to improve the quality of services delivery for patients. In addition, it has perceived threats on the quality of specimen collected, patient's safety, and health care.
Sections du résumé
BACKGROUND
BACKGROUND
The focus of the community anti-retroviral therapy Group model is on drug refill, adherence and support groups. However, laboratory services are completely neglected in this model, and stable patient still have to go to the clinic for blood draws after drugs refills from the community. Due to the introduction of new ART drugs, the guidelines now recommend the use of viral loads to guide decision in switching all patients from NNRTI to dolutegravir based first line ART regimens. But the national viral load testing coverage stands at 37% and and falls short of meeting the global UNAIDS and phlebotomy delivery system is congested. The purpose of this study was to identify the perceptions in decentralizing phlebotomy services into the community anti-retroviral therapy Group model.
METHOD
METHODS
A qualitative case study design was used. Data were collected through ten Focused group discussions among community anti-retroviral therapy Group members, community and health care workers at anti-retroviral therapy clinics and in-depth interviews with five key informants. Data were managed with the help of Nvivo version 10 and analyzed using thematic method.
RESULTS
RESULTS
Positive perceptions were identified as those which contributed to decongesting phlebotomy rooms, reduced missing phlebotomy appointments, work Load, and lost results. Improved quality of phlebotomy service delivery and testing coverage, innovative access to laboratory services and encouraged patient's accountability. The negative perceptions were compromised sample integrity, inability to perform prevention control and patients less contact with clinicians.
CONCLUSION
CONCLUSIONS
The study has demonstrated that decentralizing phlebotomy services within the CAG model has greater potential to improve the quality of services delivery for patients. In addition, it has perceived threats on the quality of specimen collected, patient's safety, and health care.
Identifiants
pubmed: 31412849
doi: 10.1186/s12913-019-4386-5
pii: 10.1186/s12913-019-4386-5
pmc: PMC6694622
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
570Références
CAP Today. 2001 Feb;15(2):12-4, 16, 18
pubmed: 11273204
Science. 2002 Mar 15;295(5562):2036-9
pubmed: 11896266
Emerg Infect Dis. 2004 Oct;10(10):1872-3
pubmed: 15504282
J Consult Clin Psychol. 2005 Oct;73(5):852-60
pubmed: 16287385
MLO Med Lab Obs. 2005 Oct;37(10):24-5, 28
pubmed: 16295181
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001442
pubmed: 16855968
Homeopathy. 2006 Oct;95(4):215-22
pubmed: 17015192
J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):71-6
pubmed: 17031319
Fam Pract. 2008 Apr;25(2):127-31
pubmed: 18304975
Adm Policy Ment Health. 2009 Jan;36(1):24-34
pubmed: 19104929
BMC Health Serv Res. 2009 Jan 09;9:5
pubmed: 19134202
PLoS Med. 2009 Jan 27;6(1):e11
pubmed: 19175285
Trans R Soc Trop Med Hyg. 2009 May;103(5):533-4; author reply 534-5
pubmed: 19187947
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):e39-44
pubmed: 21084990
AIDS Rev. 2010 Oct-Dec;12(4):195-208
pubmed: 21179184
Eur J Gastroenterol Hepatol. 2013 Apr;25(4):469-73
pubmed: 23325274
BMC Health Serv Res. 2013 Aug 01;13:291
pubmed: 23902601
BMC Public Health. 2013 Aug 15;13:756
pubmed: 23947336
Int Health. 2013 Sep;5(3):169-79
pubmed: 24030268
PLoS One. 2014 Jan 02;9(1):e84317
pubmed: 24392124
PLoS One. 2014 Mar 20;9(3):e91544
pubmed: 24651523
BMC Public Health. 2014 Apr 15;14:364
pubmed: 24735550
Trop Med Int Health. 2014 Dec;19(12):1397-410
pubmed: 25227621
BMC Public Health. 2016 Jan 05;16:5
pubmed: 26729328
Biochem Med (Zagreb). 2016;26(1):17-33
pubmed: 26981016
J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20841
pubmed: 27443271
PLoS One. 2017 Jul 27;12(7):e0182005
pubmed: 28750083
Afr J Lab Med. 2014 Aug 18;3(1):132
pubmed: 29043181
BMJ. 1995 Jul 1;311(6996):42-5
pubmed: 7613329
Eur J Haematol. 1999 Jan;62(1):1-18
pubmed: 9918306